This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk (NVO) to Expand Manufacturing Site in France
by Zacks Equity Research
Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand
by Zacks Equity Research
Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer's (PFE) New Products May Drive Long-Term Sales Growth
by Kinjel Shah
Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.
The Zacks Analyst Blog Highlights Meta Platforms, Walmart, Pfizer, Intel and Ecolab
by Zacks Equity Research
The Zacks Analyst Blog Highlights Meta Platforms, Walmart, Pfizer, Intel and Ecolab
Top Analyst Reports for Meta Platforms, Walmart & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and Pfizer Inc. (PFE).
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
by Zacks Equity Research
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.
Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla
by Zacks Equity Research
Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.
Earnings Estimates Come Under Pressure
by Sheraz Mian
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.
Earnings Estimates Come Under Pressure
by Sheraz Mian
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
by Zacks Equity Research
Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.
Markets Wait for Fed's FOMC Meeting Decisions
by Zacks Equity Research
Markets Wait for Fed's FOMC Meeting Decisions.
UAW Wins; CAT & PFE Beat, Fall in Pre-Market
by Mark Vickery
This morning, a muted version of yesterday's bull market continues: the Dow is +2 points, and the S&P 500 and the Nasdaq are +6.
Compared to Estimates, Pfizer (PFE) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 46.88% and 3.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.
Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY
by Zacks Equity Research
Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.
Pre-Markets in Green to Start a Crucial Week of Events
by Zacks Equity Research
Pre-Markets in Green to Start a Crucial Week of Events.
Busy Week for Earnings, Fed, Reports; MCD, ON Beat in Q3
by Mark Vickery
Mid-October near-term highs have given way to lower trading levels for the most part in the past couple weeks.
The Zacks Analyst Blog Highlights Costco Wholesale, Pfizer, IBM, NextEra Energy and HCA Healthcare
by Zacks Equity Research
Costco Wholesale, Pfizer, IBM, NextEra Energy and HCA Healthcare are part of the Zacks top Analyst Blog.
Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Top Research Reports for Costco, Pfizer & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp. (COST), Pfizer Inc. (PFE) and IBM Corp. (IBM).
Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products
by Kinjel Shah
Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh
AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 3.15% and 1.65%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?